The next-generation sequencing revolution is enabling unprecedented access to causal genes underlying a variety of disease conditions. This information promises to lead to more effective and increasingly personalized therapeutics as new disease mechanisms are characterized and target genes are identified. A critical bottleneck in leveraging this information to the point of defining new treatments, however, is the development of safe and effective therapeutics, which are often small molecules that bind the protein target of interest. Even with a well-defined target, development of small molecule probes is expensive and inefficient, which is why it can take years or even decades of drug development from discovery of the disease mechanism to an FDA approved drug. The proposed research addresses this bottleneck with the long-term goal of rapidly characterizing novel compounds' modes of action to build a comprehensive small molecule library targeting a significant fraction of the human genome. The specific objective of this application is to develop key computational infrastructure for high-throughput chemical genomics approaches, which leverage model organism mutant libraries as a diagnostic for compound target discovery. This objective will be accomplished through three specific aims: (1) the development of an experimental pipeline and computational infrastructure for chemical genetic interaction mapping in S. cerevisiae, S. pombe, and E. coli and application of the approach to large libraries of natural products or synthetic compound libraries, (2) the development of methods for combining chemical-genetic and genetic interactions to predict mode-of-action for large compound libraries, and (3) the development and experimental validation of predictive models for compound synergy. The proposed research is innovative because it closely integrates computational approaches leveraging the structure of genetic interaction networks with optimization of a powerful experimental assay. Furthermore, it challenges the current paradigm of target-centric therapeutic development as well as the notion of an inherent tradeoff in compound screening throughput when chemical genomic approaches are used. The proposed work will demonstrate that chemical genomics can be scaled to accommodate the largest of chemical libraries while providing an unbiased strategy for identifying novel modes of action. Other expected outcomes include (1) the discovery of hundreds of new small molecule probes with precise modes of action, (2) methods for integrating genome-scale data across species to improve the relevance of model organism chemical- genetic data to human health, (3) fundamental characterization of how the diversity of natural products interacts with eukaryotic cells on a global scale, and (4) mechanistic understanding, predictive models, as well as several novel discoveries of compound combinations that act synergistically.

Public Health Relevance

Genome sequencing and related technologies are generating candidate drug targets for a variety of diseases at an unprecedented pace. However, the process of identifying new chemicals to target these proteins is becoming increasingly inefficient. This project proposes to develop a new chemical genomic approach that will support rapid discovery of synthetic compounds or natural products with the potential to be effective therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Research Project (R01)
Project #
5R01HG005084-06
Application #
9062476
Study Section
Biodata Management and Analysis Study Section (BDMA)
Program Officer
Pillai, Ajay
Project Start
2009-07-01
Project End
2017-04-30
Budget Start
2016-05-01
Budget End
2017-04-30
Support Year
6
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Biostatistics & Other Math Sci
Type
Biomed Engr/Col Engr/Engr Sta
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
VanderSluis, Benjamin; Costanzo, Michael; Billmann, Maximilian et al. (2018) Integrating genetic and protein-protein interaction networks maps a functional wiring diagram of a cell. Curr Opin Microbiol 45:170-179
Kayatekin, Can; Amasino, Audra; Gaglia, Giorgio et al. (2018) Translocon Declogger Ste24 Protects against IAPP Oligomer-Induced Proteotoxicity. Cell 173:62-73.e9
Kuzmin, Elena; VanderSluis, Benjamin; Wang, Wen et al. (2018) Systematic analysis of complex genetic interactions. Science 360:
Nelson, Justin; Simpkins, Scott W; Safizadeh, Hamid et al. (2018) MOSAIC: a chemical-genetic interaction data repository and web resource for exploring chemical modes of action. Bioinformatics 34:1251-1252
Ciftci-Yilmaz, Sultan; Au, Wei-Chun; Mishra, Prashant K et al. (2018) A Genome-Wide Screen Reveals a Role for the HIR Histone Chaperone Complex in Preventing Mislocalization of Budding Yeast CENP-A. Genetics 210:203-218
Bottoms, Scott; Dickinson, Quinn; McGee, Mick et al. (2018) Chemical genomic guided engineering of gamma-valerolactone tolerant yeast. Microb Cell Fact 17:5
Morales, Eduardo H; Pinto, Camilo A; Luraschi, Roberto et al. (2017) Accumulation of heme biosynthetic intermediates contributes to the antibacterial action of the metalloid tellurite. Nat Commun 8:15320
Adnani, Navid; Chevrette, Marc G; Adibhatla, Srikar N et al. (2017) Coculture of Marine Invertebrate-Associated Bacteria and Interdisciplinary Technologies Enable Biosynthesis and Discovery of a New Antibiotic, Keyicin. ACS Chem Biol 12:3093-3102
Wang, Wen; Xu, Zack Z; Costanzo, Michael et al. (2017) Pathway-based discovery of genetic interactions in breast cancer. PLoS Genet 13:e1006973
Piotrowski, Jeff S; Li, Sheena C; Deshpande, Raamesh et al. (2017) Functional annotation of chemical libraries across diverse biological processes. Nat Chem Biol 13:982-993

Showing the most recent 10 out of 44 publications